Verona Pharma plc
VRNA
$65.46
$0.681.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -33.83M | -42.96M | -70.84M | -25.79M | -14.13M |
| Total Depreciation and Amortization | 259.00K | 266.00K | 270.00K | 263.00K | 208.00K |
| Total Amortization of Deferred Charges | 527.00K | 777.00K | -- | -- | 13.00K |
| Total Other Non-Cash Items | 19.08M | -9.92M | 40.78M | 4.65M | 3.39M |
| Change in Net Operating Assets | -14.88M | -10.82M | 12.69M | 7.27M | 124.00K |
| Cash from Operations | -28.84M | -62.66M | -17.10M | -13.61M | -10.40M |
| Capital Expenditure | -535.00K | 0.00 | -29.00K | -16.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -535.00K | 0.00 | -29.00K | -16.00K | -- |
| Total Debt Issued | 0.00 | 0.00 | 122.50M | -- | 28.71M |
| Total Debt Repaid | 0.00 | 0.00 | -52.26M | -- | -- |
| Issuance of Common Stock | 98.42M | 3.67M | 0.00 | 816.00K | -- |
| Repurchase of Common Stock | -4.26M | -6.14M | -1.47M | -3.58M | -4.69M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -4.61M | 98.06M | -364.00K | -12.00K |
| Cash from Financing | 94.16M | -7.09M | 166.83M | -3.12M | 24.01M |
| Foreign Exchange rate Adjustments | -1.07M | 1.18M | 16.00K | -141.00K | 796.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 63.72M | -68.56M | 149.72M | -16.89M | 14.41M |